Psilocybin-Assisted Therapy May Enhance Conservation Values in Patients with Alcohol Use Disorder
Noah D Gold, Broc A. Pagni, Petros Petridis, Michael P. Bogenschutz
Psychedelic Medicine November 25, 2024 DOI: 10.1089/psymed.2024.0030 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Phase II randomized controlled trial Peer reviewed |
|---|---|
| Sample size | 93 |
| Population | Patients with alcohol use disorder |
| Interventions | Psilocybin active placebo |
| Duration | 12 weeks of treatment including two 8-hour drug administration sessions |
| Topics | Addiction Psilocybin |
| Keywords | Hallucinogen Psychotherapist Pharmacology |
| Citations | 3 |
| Registration | NCT02061293 |
| Key findings | Psilocybin-assisted therapy increased Conservation values (security and tradition) in patients with alcohol use disorder, but these value changes were not associated with drinking outcomes. |
Abstract
Background: Psilocybin can produce long-term changes in personality, personal values, and behavior. Although psilocybin-assisted therapy (PAT) is being actively studied for various psychiatric conditions, its effects on personal values in patients with alcohol use disorder (AUD) remain unexplored. This study examined the effects of PAT on personal values in patients with AUD and assessed relationships between value changes, acute psilocybin experiences, and drinking outcomes.
Methods: In a phase II clinical trial (NCT02061293), 93 participants with AUD received 12 weeks of treatment, including manualized psychotherapy and two 8-h drug administration sessions with either psilocybin ( n = 48) or active placebo ( n = 45). Personal values were assessed before and after treatment using the Schwartz Value Survey (SVS), which includes 4 domain scores (Openness to Change, Self-Enhancement, Conservation, Self-Transcendence) and 10 subscales. The acute psychedelic experience was measured using the 30-item Mystical Experience Questionnaire (MEQ) and the 5-Dimensional Altered States of Consciousness Scale (5D-ASC). Treatment effects were assessed using univariate ANCOVAs, with baseline SVS values as covariates. Time effects within each group were evaluated using paired t -tests. Pearson correlations examined the relationship between value changes and acute effects, and also value changes and drinking outcomes.
Results: Significant treatment effects were detected for the Conservation domain and its subscales “security” and “tradition.” No other domains or subscales showed significant treatment effects. Within the psilocybin group, time effects were significant only for conservation, and its subscales “tradition,” and “security”. No significant time effects were detected in the placebo group. In the psilocybin group, the MEQ subscale Ineffability was significantly associated with increases in Conservation, “security,” and “tradition” ( r = 0.31–0.34). 5D-ASC subscale Vigilance Reduction was associated with Conservation ( r = 0.31), but not its subscales. 5D-ASC subscale Dread of Ego Dissolution during the psilocybin sessions correlated with increases in “tradition” ( r = 0.31). None of the value changes were significantly associated with drinking outcomes.
Conclusion: PAT may alter value structure in patients with AUD patients by increasing Conservation. Although some associations were found between acute psychedelic effects and changes in Conservation, these value changes were not related to drinking outcomes.
Comparable studies
Other randomized controlled trials on psilocybin for addiction, most cited first.
Citations in the library
Cited by 3
- Psilocybin in Alcohol Use Disorder Maintains Abstinence Efficacy: A Scoping Review Qeios December 9, 2025
- A Tragedy of Errors: The State of Psychedelic Research in the Treatment of Alcohol Use Disorder. Brain Sciences November 4, 2025
- Psilocybin-assisted psychotherapy for substance use disorders as a complex intervention: A systematic review of efficacy, mechanisms and psychotherapeutic frameworks Journal of Psychopharmacology August 17, 2026
Cites 31
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Journal of Psychopharmacology November 30, 2016
- Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry May 17, 2016
- Trial of Psilocybin versus Escitalopram for Depression New England Journal of Medicine April 14, 2021
- Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder JAMA Psychiatry November 4, 2020
and 26 more in the library